VYNE Therapeutics Inc
For the period ended Jun 30, 2024. Filed Aug 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 14, 2024
YARW$15.48-2.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unaudited Condensed Consolidated Balance Sheets
CONDENSED CONSOLIDATED BALANCE SHEETS
(U.S. dollars in thousands, except share and per share data)
| June 30, | December 31, | |
|---|---|---|
| 2024 | 2023 | |
| Assets | ||
| Current Assets: | ||
| Cash and cash equivalents | $29,609 | $30,620 |
| Restricted cash | 46 | 54 |
| Investment in marketable securities | 48,492 | 62,633 |
| Prepaid and other current assets | 5,629 | 2,656 |
| Total Current Assets | 83,776 | 95,963 |
| Non-current Assets: | ||
| Operating lease right-of-use assets | 151 | 207 |
| Non-current prepaid expenses and other assets | 2,721 | 1,515 |
| Total Non-current Assets | 2,872 | 1,722 |
| Total Assets | $86,648 | $97,685 |
| Liabilities and Stockholders’ Equity | ||
| Current Liabilities: | ||
| Trade payables | $4,516 | $1,659 |
| Accrued expenses | 5,069 | 4,119 |
| Employee related obligations | 736 | 1,645 |
| Operating lease liabilities | 120 | 115 |
| Other current liabilities | 1,313 | — |
| Total Current Liabilities | 11,754 | 7,538 |
| Long-term Liabilities: | ||
| Non-current operating lease liabilities | 25 | 99 |
| Other liabilities | — | 1,313 |
| Total Long-term Liabilities | 25 | 1,412 |
| Total Liabilities | 11,779 | 8,950 |
| Commitments and Contingencies | ||
| Stockholders' Equity: | ||
| Preferred stock: $0.0001 par value; 20,000,000 shares authorized at June 30, 2024 and December 31, 2023; no shares issued and outstanding at June 30, 2024 and December 31, 2023 | — | — |
| Common stock: $0.0001 par value; 150,000,000 shares authorized at June 30, 2024 and December 31, 2023; 14,536,124 and 14,098,888 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively | 1 | 1 |
| Additional paid-in capital | 781,917 | 780,044 |
| Accumulated other comprehensive (loss) income | (58) | 26 |
| Accumulated deficit | (706,991) | (691,336) |
| Total Stockholders' Equity | 74,869 | 88,735 |
| Total Liabilities and Stockholders’ Equity | $86,648 | $97,685 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.